NCT05471206终止不适用
Evaluation of Gastrointestinal pH and Motility by Using the SmartPill® Motility Capsules After the Consumption of Milk in Symptomatic Milk Intolerant and Asymptomatic Subjects
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- Lactalis
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- The primary endpoint in this study is the AUC of pH, defined between 0 and 120 minutes after ingestion of milk, expressed in pH.min.
研究概览
简要总结
This pilot study is designed as a monocentric, open label, interventional, parallel arms, controlled clinical trial. The aim of the study is to assess the gastrointestinal pH and motility after the consumption of milk.
The clinical study is categorized as an interventional research involving the human person with low risks and constraints (RIPH 2) and which does not assess a health product.
The milk and medical device used in this clinical study are both authorized and already commercialized in France.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age between 18 and 40 years (limits included),
- •BMI between 18.5 and 30 kg/m² (limits included),
- •Able and willing to drink 250mL of milk in 5 minutes,
- •Good general and mental health with in the opinion of the investigator: no clinically significant and relevant abnormalities of medical history or clinical examination,
- •Able and willing to participate to the study by complying with the protocol procedures as evidenced by his dated and signed informed consent form,
- •Affiliated with a social security scheme,
- •For milk intolerant subjects: self-reporting symptoms after drinking milk and drinking less than 150mL of cow's milk (lactose-free milk not included) per week (assessed by the gastrointestinal symptoms questionnaire filled out at V0).
- •For milk tolerant subjects: drinking at least 700mL of cow's milk (lactose-free milk not included) per week (assessed by the gastrointestinal symptoms questionnaire filled out at V0).
排除标准
- •Suffering from a metabolic disorder such as diabetes, uncontrolled thyroidal trouble, uncontrolled arterial hypertension or other metabolic disorder,
- •Suffering from a severe chronic disease (e.g. cancer, HIV, renal failure, hepatic or biliary disorders ongoing, chronic inflammatory digestive disease, arthritis, etc.) or disorders found to be inconsistent with the conduct of the study by the investigator,
- •Suffering from any obstructive or restrictive respiratory syndrome (COPD, asthma, etc.) that may impact breath test measurements,
- •Suffering from a gastro-intestinal pathology (inflammatory bowel disease, Crohn disease, ulcerative colitis, irritable bowel syndrome, celiac disease, gluten hypersensitivity, small intestinal bacterial overgrowth, diverticulitis, polyps, constipation, esophageal motility abnormality, history of gastric bezoar...), or other gastro-intestinal disorders found to be inconsistent with the conduct of the study by the investigator,
- •Suffering from any disorder found to be inconsistent with the conduct of the study by the investigator,
- •With a history of gastro-intestinal surgery (only appendectomy is accepted),
- •With swallowing problems,
- •With a known or suspected allergy to cows' milk protein,
- •With a lactose intolerance diagnosed by a positive Lactose Breath Test,
- •Pregnant or lactating women or intending to become pregnant during the study,
- •Under treatment or dietary supplement which could significantly affect the gut motility and/or interfere with gastric emptying time and/or affect the gut pH during the study according to the investigator or stopped less than 15 days before the V0 visit (examples: NSAIDs, proton pump inhibitors, prokinetics, treatments against diarrhea or constipation, etc.),
- •Regular intake of dietary supplements containing prebiotics, probiotics or symbiotics, or stopped less than 3 months before the V0 visit,
- •With significant change in food habits or in physical activity in the 3 months before the V0 visit or not agreeing to keep them unchanged throughout the study,
- •Weight loss or gain > 5% of body weight in the 6 months before the study,
- •With a current diet or stopped less than 3 months before the study,
- •With a current eating disorder (anorexia nervosa, bulimia, etc.) according to the investigator,
- •Consuming more than 2 standard drinks of alcoholic beverage daily regularly and not agreeing to keep alcohol consumption habits unchanged throughout the study,
- •Smoker (electronic cigarette not allowed),
- •Consuming illicit drugs,
- •Having an implanted or portable electro-mechanical medical device (such as pacemakers, defibrillators, infusion pumps…etc),
- •Taking part in another clinical trial or being in the exclusion period of a previous clinical trial,
- •Under legal protection (guardianship, wardship) or deprived from his rights following administrative or judicial decision,
- •Presenting a psychological or linguistic incapability to sign the informed consent,
- •Impossible to contact in case of emergency.
研究组 & 干预措施
Milk intolerant volunteers
Experimental
干预措施: Milk and SmartPill intakes (Other)
Milk tolerant volunteers
Active Comparator
干预措施: Milk and SmartPill intakes (Other)
结局指标
主要结局
The primary endpoint in this study is the AUC of pH, defined between 0 and 120 minutes after ingestion of milk, expressed in pH.min.
时间窗: 2 hours
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult SubjectsGastroesophageal Reflux DiseaseNCT03069963Sanofi24
已完成
1 期
Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsHealthy ParticipantsNCT04470778Bristol-Myers Squibb35
尚未招募
不适用
Comparison of GI tract pH and motility between patients with ulcerative colitis and healthy controlslcerative colitisJPRN-jRCTs052210199akamura Shiro25
已完成
1 期
A Trial to Evaluate the Effect of Esomeprazole on the Pharmacokinetics of Emraclidine in Healthy Adult ParticipantsHealthy ParticipantsNCT06366243Cerevel Therapeutics, LLC20
已完成
不适用
Monitoring Stomach Function With an Intragastric Balloon - a PilotFunctional Disorders of StomachNCT03500887Prof Dr Jan Tack6